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Abstract 
Primary retroperitoneal müllerian adenocarcinoma (PRMA) is an extremely rare clinical  
entity. We report the case of a 54-year-old woman who presented with a mass in the right 
lower retroperitoneum, identified during an ultrasound exam. Computed tomography 
confirmed a retroperitoneal mass measuring 11 cm. The patient underwent laparotomy and 
the mass was completely excised. The histopathological exam revealed PRMA. 
© 2013 S. Karger AG, Basel 
Introduction 
A malignant mixed müllerian tumor (MMMT) that develops from the female genital tract 
is a rare clinical entity, accounting for less than 1% of all gynecological malignancies [1]. 
Since müllerian ducts develop to form the fallopian tubes, uterus and the upper third of the 
vagina, MMMTs are usually found in these structures or, sometimes, in the ovary. 
There are also extremely rare MMMTs of extragenital origin: they can arise from the 
peritoneum or be retroperitoneal [2–5]. To the best of our knowledge, primary retroperito-
neal müllerian adenocarcinoma (PRMA) has been reported in only 6 cases in the literature to 
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aggressive. Its growth pattern and size are variable, and histological evaluation shows both 
carcinoma (epithelial) and sarcoma (mesenchymal) components; thus, the disorder is also 
called ‘carcinosarcoma’. Here, we report the case of PRMA in a 54-year-old woman, 
underlining its clinical, radiological and surgical features, and a review of the literature. 
Case Report 
A 54-year-old primiparous woman presented with a 6-month history of mild abdominal 
pain and distension of the right portion of the abdomen. Her family history was not 
contributory. Her past surgical history included a total thyroidectomy for papillary 
carcinoma followed by radioiodine therapy 3 years before. 
Physical examination revealed a slightly tender, ill-defined mass over the left abdomen. 
The remaining systemic examination did not reveal any coexistent lesion. Laboratory tests, 
including complete blood count, chemistry profile, urinalysis and chest X-ray, were all within 
normal limits. Serum tumor markers were negative. 
An abdominal ultrasound (US) documented the presence of a coarse, partially cystic 
mass in the right retroperitoneal region. Abdominopelvic CT and MRI revealed a large 
unilocular cystic mass measuring 11 cm with an enhancing solid portion and partial water 
content, located in the retroperitoneal space adjacent to the lower pole of the right kidney, 
with wall calcifications (fig. 1). There was no evidence of extracystic extension or distant 
metastasis. On suspicion of a hydatid cyst, serological tests were performed and yielded 
negative results. A gynecological examination, including hysteroscopy and Pap smear, was 
also performed. It was negative for utero-adnexal pathology. 
The patient underwent laparotomy with subcostal transverse incision. On opening the 
peritoneal cavity, ascitic fluid was found and sampled. Cytological examination of the fluid 
did not reveal the presence of malignant cells. Abdominal cavity exploration revealed no 
abnormal findings in the liver, stomach, large bowel and spleen, and the uterus, ovaries, 
fallopian tubes and appendix were all normal. Sequential exploration of the small intestine 
revealed the presence of an exophytic lesion about 1 cm in diameter, which was removed 
and whose definitive histological examination was compatible with fibroma of the small 
intestine. A large, encapsulated cystic mass was found in the right retroperitoneum, below 
the lower pole of the right kidney that was displaced posteriorly and cranially to the mass. 
The cecum, right colon and right colic flexure were displaced medially to the mass. The mass 
was dissected from the surrounding structures. A fragment of the cystic wall was sent for 
extemporaneous histological examination and it was compatible with a fibrous wall denuded 
of lining epithelium. Complete excision of the cyst was performed. The postoperative period 
was uneventful, and the patient was discharged home 5 days after surgery. 
The gross pathological findings showed a 12 × 10-cm cystic mass with a smooth surface. 
The cystic wall measured 0.3 cm at maximum thickness. The tumor was composed of 
malignant epithelial and stromal components. Microscopically, the fibrous wall of the cyst 
delimited an extensively necrotic lesion containing chronic inflammation, calcification, 
cholesterol crystals and hemorrhagic extravasation. On hematoxylin and eosin staining, the 
entire tumor showed cellular whorls dispersed amidst pale sarcomatous stroma. The cells in 
whorls were round to short, spindle shaped and had moderate mitotic activity. The sections, 
however, revealed whorled glandular areas. 
A panel of immunohistochemical tests was performed: whorled glandular areas were 
positive for cytokeratin (CK19) and negative for vimentin, confirming their epithelial nature; 
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highlighted on vimentin stain (vimentin), was positive for CD10. No immunoreactivity to 
estrogen and progesterone receptors was found. The presence of necrosis, cytonuclear 
atypia and immunophenotypic features were compatible with PRMA (fig. 2). 
Six courses of adjuvant chemotherapy were administered with carboplatin at a dose of 
5 AUC and taxol 175 mg/mq/ev. A follow-up abdominal CT, performed 9 months later, was 
negative for tumor recurrence. Written informed consent was obtained from the patient for 
publication of this case report and all accompanying images. 
Discussion 
Extragenital MMMTs occur infrequently. Patients usually present with specific clinical 
symptoms including abdominal distension, pain and/or a palpable mass [6]. The exact 
pathogenesis of PRMA is still unknown: Elnemr et al. [2] hypothesized that this tumor arises 
from residual hormone-independent cells of Müller ducts in the retroperitoneum, based on 
correlations with endometriosis and irradiation [5, 7, 8]. 
In our patient we found no evidence which could be linked to endometrial implants or 
even a history of abdominal or pelvic irradiation, except for a radioactive iodine treatment. 
The preoperative diagnostic management includes US, CT and, if necessary, MRI [3]. 
Preoperative diagnosis is rarely suspected because of the nonspecific symptoms and the 
scarce aid of imaging examinations. Although US, CT and MRI clearly detect cystic masses in 
ovarian or pelvic organs, diagnosis of a retroperitoneal tumor is extremely difficult [6]. 
When radiological exams do not reveal evidence of metastatic disease, patients must 
undergo laparotomy with the aim of eradicating the tumor completely. Due to its strong 
aggressiveness, it is recommended not to break the tumor mass during surgical eradication 
maneuvers, in order to avoid any peritoneal implantation [2, 9, 10]. 
It was considered that the biological behavior of PRMA resembled that of epithelial 
ovarian cancer, so patients have been treated in a similar way, using the same regimen of 
adjuvant chemotherapy for ovarian tumors; the role of radiotherapy remains controversial 
[1, 11, 12]. As shown in the literature, because of the very small number of cases thus far 
presented, no evidence-based management guidelines are available. 
Further studies will be needed to determine the correct therapeutic strategy to follow, 
evaluating long-term follow-up, course and prognosis of this disease. 
Disclosure Statement 
The authors declare that they have no competing interests. 
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Table 1. Reports of primary retroperitoneal and peritoneal müllerian adenocarcinomas 
        
        
Study (first author) Age, 
years 





        
        
Ferrie, 1967 [8] 47 Retroperitoneal 11 Cystic Previous  
hydatidiform mole 
NS NS 
                Booth, 2004 [7] 71 Retroperitoneal space 9 × 7 × 6.5 Solid and cystic Uterine  
leiomyomata 
Pelvic RT NED 32 months 
                de León, 2007 [6] 36 Retroperitoneal space 19 × 16 × 12 Solid and cystic None CT AWD 9 months 
                de León, 2007 [6] 21 Retroperitoneal space 26 × 18 × 16 Solid and cystic None Patient 
refused CT 
NED 6 months 
                Iura, 2009 [9] 66 Retroperitoneal space 20 × 9.5 × 8.5 Solid and cystic Serous  
adenocarcinoma 
CT AWD 32 
months 
                Elnemer, 2010 [2] 46 Retroperitoneal space 15 × 10 Cystic None CT AWD 6 months 
                Kanis, 2011 [5] 80 Peritoneal 15 × 10 Solid None CT DOD 4 months 
                Kanis, 2011 [5] 57 Peritoneal 15 × 20 × 15 Solid and cystic None CT NED 4 months 
                Berretta, 2013 [4] 72 Peritoneal 33 × 33 × 11 Solid and cystic None NS NED 12 months 
                Present report, 2013  54 Retroperitoneal space 11 × 10 Cystic None CT NED 9 months 
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Fig. 2. Histopathological findings. MMMT, also known as carcinosarcoma, is composed of malignant 
epithelial and stromal components. Glandular epithelial (a–e) and sarcomatous (f) elements of the lesion. 
On hematoxylin and eosin (H&E) staining, the whole mass shows cellular whorls dispersed amidst pale 
sarcomatous stroma. a H&E. ×40. b H&E. ×20. c H&E. ×20. d H&E. ×40. e Positivity for cytokeratin (CK19) 
of whorled glandular areas confirms their epithelial nature. f Vimentin reveals the sarcomatous nature of 
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